Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 70 HER2-positive Breast Cancer 15 Carcinoma, Non-Small-Cell Lung 6 HER2 Positive Metastatic Breast Cancer 4 Breast Diseases 4 Brain Neoplasms 4 HER2 Positive Breast Cancer 3 Advanced Breast Cancer 3 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Salivary Gland Neoplasms 2 HER2-positive Metastatic Breast Cancer 2 Colorectal Neoplasms 2 Breast Cancer Invasive 2 Breast Cancer Female 2 Solid Tumor 1 Rare Tumour 1 Rare Tumor 1 Pathologic Complete Response 1 Non-squamous NSCLC 1 Non Small Cell Lung 1 Neoplasm Metastasis 1 Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1 Metastatic Breast Cancer in the Brain 1 Lung Neoplasms 1 Locally Advanced Breast Cancer 1 HER2-positive Early Breast Cancer 1 HER2-positive Advanced Breast Cancer 1 HER2-expressing Advanced Solid Tumors 1 HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane 1

Interventions

Carboplatin 345 Cisplatin 240 Paclitaxel 208 Radiotherapy 206 Pemetrexed 190 Docetaxel 170 Gemcitabine 158 pembrolizumab 146 Erlotinib Hydrochloride 111 Magnetic Resonance Spectroscopy 101 Etoposide 98 Bevacizumab 96 Specimen Handling 84 Nivolumab 77 durvalumab 73 Radiosurgery 73 Blood Specimen Collection 65 Drug Therapy 61 osimertinib 56 Vinorelbine 54 Gefitinib 50 Surveys and Questionnaires 48 atezolizumab 44 Biopsy 43 Irinotecan 42 Radiation 41 Topotecan 39 Standard of Care 38 Cyclophosphamide 38 Surgical Procedures, Operative 35

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lung Neoplasms × pyrotinib × Clear all

NCT06563999 2026-04-21

NUMER

Sun Yat-sen University

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡